Cerebrospinal fluid prostate specific antigen (CSF PSA) in prostate cancer patients with lower spine metastasis

Basit Öğe Kaydı
dc.contributor.authorŞahin, Hayrettin
dc.contributor.authorAflay, Uǧur
dc.contributor.authorBatun, Sabri
dc.contributor.authorBircan, Mehmet Kamuran
dc.contributor.orcid0000-0003-3311-3530
dc.date.accessioned2024-04-24T17:56:05Z
dc.date.available2024-04-24T17:56:05Z
dc.date.issued2005
dc.departmentDicle Üniversitesien_US
dc.description.abstractAim: In this prospective study, our aim was to investigate the CSF PSA levels and CSF/Serum PSA ratios in patients with prostate cancer with lower spine metastasis. Methods: The study involved patients with prostate cancer (n= 15), benign prostatic hyperplasia (n= 17) and non-prostatic disease (n= 9). Serum and CSF were obtained prior to spinal anesthesia for urological surgery. Total PSA levels in the serum and CSF were measured by electrochemiluminescence immunoassay. The results were tested statistically using the Mann-Whitney U test. Results: The mean serum PSA levels were 20.36 ng/ml in the prostate cancer patients, 5.37 ng/ml in the BPH patients and 0.76 ng/ml non-prostatic disease. The mean CSF PSA levels in groups were 0.127, 0.051 and 0.027 ng/ml, respectively. The mean CSF PSA/serum PSA ratios in groups were 0.007, 0.018 and 0.042, respectively. This result is statistically significant (P< 0.001). Conclusions: Although mean serum PSA and CSF PSA levels in the patients with cancer of the prostate and lower spine metastasis are higher than those in the others, the mean CSF PSA/serum PSA ratio is lower. However, clinical usefulness of CSF PSA value and CSF PSA/ Serum PSA ratio can be limited because CSF PSA values are usually very low, and CSF PSA/Serum PSA ratio of 4 prostate cancer patients are as high as 1 BPH patient.en_US
dc.identifier.citationŞahin, H., Aflay, U., Batun, S. ve Bircan, M. K. (2005). Cerebrospinal fluid prostate specific antigen (CSF PSA) in prostate cancer patients with lower spine metastasis. International Urology and Nephrology, 37(4), 727-730.
dc.identifier.doi10.1007/s11255-005-8438-x
dc.identifier.endpage730en_US
dc.identifier.issn0301-1623
dc.identifier.issue4en_US
dc.identifier.pmid16362588
dc.identifier.scopus2-s2.0-31144441651
dc.identifier.scopusqualityQ2
dc.identifier.startpage727en_US
dc.identifier.urihttps://doi.org/10.1007/s11255-005-8438-x
dc.identifier.urihttps://hdl.handle.net/11468/23271
dc.identifier.urihttps://link.springer.com/article/10.1007/s11255-005-8438-x
dc.identifier.volume37en_US
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.relation.ispartofInternational Urology and Nephrology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCerebrospinal fluiden_US
dc.subjectProstate canceren_US
dc.subjectProstate-specific antigenen_US
dc.titleCerebrospinal fluid prostate specific antigen (CSF PSA) in prostate cancer patients with lower spine metastasisen_US
dc.titleCerebrospinal fluid prostate specific antigen (CSF PSA) in prostate cancer patients with lower spine metastasis
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
Cerebrospinal fluid prostate specific antigen (CSF PSA) in prostate cancer patients with lower spine metastasis.pdf
Boyut:
153.06 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu